Milnacipran Arrow (Milnacipran Hydrochloride)

Milnacipran, the active ingredient in Milnacipran Arrow, is a serotonin‑norepinephrine reuptake inhibitor (SNRI) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Milnacipran Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milnacipran is an SNRI indicated for major depressive disorder and related depressive conditions.

Major depressive disorder: reduces depressive symptoms in adult patients. Depressive episodes in bipolar disorder (adjunct): may help manage depressive phases under specialist supervision. Treatment‑resistant depression: can be considered when first‑line agents are insufficient.

Milnacipran may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea - Headache - Dry mouth - Insomnia - Dizziness - Constipation

Serious or Rare Side Effects: - Elevated blood pressure or tachycardia - Serotonin syndrome, especially with other serotonergic drugs - Suicidal thoughts or worsening depression - Severe liver injury (rare) - Hypertensive crisis

When prescribing Milnacipran, clinicians should consider several safety measures.

Assess cardiovascular status: monitor blood pressure and heart rate regularly. Screen for psychiatric history: watch for worsening depression or suicidal ideation. Avoid abrupt discontinuation: taper the dose under medical supervision. Use caution in hepatic impairment: dose adjustment may be required. Avoid concomitant MAO inhibitors: maintain an appropriate washout period. Store at ambient temperature: keep in the original container, protect from moisture and light.

Milnacipran interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, triptans, linezolid): increased serotonin toxicity. - Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): may raise milnacipran levels. - Drugs that prolong QT interval: additive cardiac risk. - MAO‑B inhibitors: potential for hypertensive reactions.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood‑pressure lowering effect. - CYP3A4 inducers (rifampin, carbamazepine): may reduce efficacy. - NSAIDs or anticoagulants: monitor for increased bleeding risk.